Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin

Detalhes bibliográficos
Autor(a) principal: Dias, Daniela
Data de Publicação: 2023
Outros Autores: Damásio, Inês, Marques, Pedro, Simões, Helder, Rodrigues, Ricardo, Cavaco, Branca Maria, Leite, Valeriano
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/155785
Resumo: Funding Information: Ricardo Rodrigues is a recipient of a PhD scholarship by iNOVA4Health Research Unit (UIDP/04462/2020; UI/BD/154256/2022), a program co-funded by Fundação para a Ciência e a Tecnologia, Portugal, and by Ministério da Ciência e do Ensino Superior, Portugal. This work was funded by Associação de Endocrinologia Oncológica (AEO) and by Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG). Publisher Copyright: © 2023 the author(s) Published by Bioscientifica Ltd.
id RCAP_3d6fb3ae9df2c78d8e5d41ae7e52690b
oai_identifier_str oai:run.unl.pt:10362/155785
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatinadvanced follicular thyroid carcinomaGEMOX (gemcitabine plus oxaliplatin)multikinase inhibitorsEndocrinology, Diabetes and MetabolismSDG 3 - Good Health and Well-beingFunding Information: Ricardo Rodrigues is a recipient of a PhD scholarship by iNOVA4Health Research Unit (UIDP/04462/2020; UI/BD/154256/2022), a program co-funded by Fundação para a Ciência e a Tecnologia, Portugal, and by Ministério da Ciência e do Ensino Superior, Portugal. This work was funded by Associação de Endocrinologia Oncológica (AEO) and by Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG). Publisher Copyright: © 2023 the author(s) Published by Bioscientifica Ltd.Background: Treatment of advanced follicular thyroid carcinoma (FTC) is based primarily on indirect evidence obtained with multikinase inhibitors (MKI) in clinical trials in which papillary carcinomas represent the vast majority of cases. However, it should be noted that MKI have a non-negligible toxicity that may decrease the patient’s quality of life. Conventional chemotherapy with GEMOX (gemcitabine plus oxaliplatin) is an off-label therapy, which seems to have some effectiveness in advanced differentiated thyroid carcinomas, with a good safety profile, although further studies are needed. Case report: We report a case of a metastatic FTC, resistant to several lines of therapy. However, with a durable response to GEMOX, the overall survival of our patient appears to have been extended significantly due to this chemotherapy. Conclusion: GEMOX may have a role in patients with thyroid cancer unresponsive to MKI.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNDias, DanielaDamásio, InêsMarques, PedroSimões, HelderRodrigues, RicardoCavaco, Branca MariaLeite, Valeriano2023-07-24T22:16:16Z2023-05-082023-05-08T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/155785eng2235-0640PURE: 67081569https://doi.org/10.1530/ETJ-22-0227info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:38:22Zoai:run.unl.pt:10362/155785Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:56:12.850845Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin
title Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin
spellingShingle Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin
Dias, Daniela
advanced follicular thyroid carcinoma
GEMOX (gemcitabine plus oxaliplatin)
multikinase inhibitors
Endocrinology, Diabetes and Metabolism
SDG 3 - Good Health and Well-being
title_short Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin
title_full Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin
title_fullStr Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin
title_full_unstemmed Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin
title_sort Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin
author Dias, Daniela
author_facet Dias, Daniela
Damásio, Inês
Marques, Pedro
Simões, Helder
Rodrigues, Ricardo
Cavaco, Branca Maria
Leite, Valeriano
author_role author
author2 Damásio, Inês
Marques, Pedro
Simões, Helder
Rodrigues, Ricardo
Cavaco, Branca Maria
Leite, Valeriano
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Dias, Daniela
Damásio, Inês
Marques, Pedro
Simões, Helder
Rodrigues, Ricardo
Cavaco, Branca Maria
Leite, Valeriano
dc.subject.por.fl_str_mv advanced follicular thyroid carcinoma
GEMOX (gemcitabine plus oxaliplatin)
multikinase inhibitors
Endocrinology, Diabetes and Metabolism
SDG 3 - Good Health and Well-being
topic advanced follicular thyroid carcinoma
GEMOX (gemcitabine plus oxaliplatin)
multikinase inhibitors
Endocrinology, Diabetes and Metabolism
SDG 3 - Good Health and Well-being
description Funding Information: Ricardo Rodrigues is a recipient of a PhD scholarship by iNOVA4Health Research Unit (UIDP/04462/2020; UI/BD/154256/2022), a program co-funded by Fundação para a Ciência e a Tecnologia, Portugal, and by Ministério da Ciência e do Ensino Superior, Portugal. This work was funded by Associação de Endocrinologia Oncológica (AEO) and by Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG). Publisher Copyright: © 2023 the author(s) Published by Bioscientifica Ltd.
publishDate 2023
dc.date.none.fl_str_mv 2023-07-24T22:16:16Z
2023-05-08
2023-05-08T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/155785
url http://hdl.handle.net/10362/155785
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2235-0640
PURE: 67081569
https://doi.org/10.1530/ETJ-22-0227
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138148048961536

Registros relacionados